postischaemia. Seven days after ischaemia, the brains were fixed by perfusion. CAl pyramidal cell counts were performed on Nissl-stained sections using an ocular grid piece. Ventilated (no ischaemia) control animals had a mean of 406 ± 13 CAl neurones/3 grid lengths. Ischaemia reduced this mean to 157 ± 23. A significant protective effect against this cell loss was seen after two injections (at 15 min and 5 h postischaemia) of 2APH, CPP (10 mg/ kg), CGS 19755 (10 mg/kg), MK801 (I mg/kg), and de x trorphan (54 mg/kg). Delayed injection (5 and 10 h post ischaemia) of CGS 19755 (10 and 30 mg/kg) and MK801 (I and 3 mg/kg) did not provide any protection against py ramidal cell loss. Key Words: Cerebral ischaemia Cerebroprotection-Hippocampus-N-Methyl-D-aspar tate antagonists-Selective cell loss.
citatory action of glutamate at the postsynaptic re ceptor early during the reperfusion phase. At this time increased burst firing is observed (Suzuki et aI., 1983) and there is enhanced neuronal influx of Ca2 + associated with acute cytopathology (Mel drum, 1983; Simon et aI., 1984b) .
Competitive NMDA antagonists such as 2APH prevent receptor activation by competing with the agonist for the transmitter recognition site. Non competitive NMDA antagonists include the disso ciative anaesthetics ketamine and phencyclidine (PCP) (Lodge and Anis, 1982) , IT-opiates and mor phinans (such as dextrorphan) (Church et aI., 1985; Choi et aI., 1987) , and the anticonvulsant MK801 (Sircar et aI., 1987; Wong et aI., 1988) . These ap pear to have a common site of action related to the ion channel.
Selective neuronal loss is evident in the CAl re gion of the hippocampus following 10 min of isch aemia and 7 days of survival (Smith et aI., 1984; Evans et aI., 1987; Swan et aI., 1988) . This study investigates the efficacy of competitive and non competitive NMDA antagonists in reducing this CAl cell loss.
H. SWAN ANDB. S. MELDRUM
The competitive NMDA antagonists investigated are the longer-chain phosphonic analogue of D glutamate 2APH, the piperazine derivative 3-[(±)-2-carboxypiperazin-4-yl]propyl-l-phosphonate (CPP) and the piperidine analogue of 2-amino-5-phosphonovalerate CGS 19755 (cis-4-phos phonomethyl-2-piperidine carboxylate).
MK801 and a morphinan derivative, dextror phan, are the two noncompetitive compounds in vestigated. All of these compounds have previously been shown to block NMDA-induced depolarisa tions (Lodge and Anis, 1982; Church et aI., 1985; Davies et aI., 1986; Kemp et aI., 1986; Lehmann et aI., 1988a,b) . 2APH, dextrorphan, and MK801 also block the neurotoxic action of NMDA and gluta mate in tissue culture (Choi, 1987; Choi et aI., 1987; Goldberg et aI., 1987 Goldberg et aI., , 1988 . Potent anticonvulsant effects of all the drugs tested have been demon strated in various animal seizure models (Cline schmidt et aI., 1982; Croucher et aI., 1982; Davies et aI., 1986; Tortello and Musacchio, 1986; Chapman et aI., 1987; Chapman and Meldrum, 1989) .
METHODS

General operative techniques
Male Wistar rats (20{}-230 g), starved overnight, were used in all experiments. Animals were anaesthetised with 2% halothane (in 70% nitrous oxide/30% oxygen) and pre medicated with atropine (240 J-lg/kg i.m.). One femoral vein and the caudal artery were cannulated. The carotid arteries were exposed and loose snares placed around each vessel. Wounds were infiltrated with 1% lignocaine. The animals were intubated and artificially ventilated (70% nitrous oxide/30% oxygen via a small animal venti lator; Harvard Apparatus). Suxamethonium chloride (20 mg/kg i.v.) was administered. MABP was monitored con tinually using an Elcomatic transducer and pen recorder. P a02' P aco2, and arterial pH were measured on a blood gas analyser (IL 1304; Warrington, U.K.). These physio logical variables were maintained within normal limits (Paco2, 35-45 mm Hg; Pa02, >100 mm Hg; pH, 7.4 ± 0.03) during the 30-min preischaemic stabilisation period. Body temperature was maintained at 37.0 ± 0.5°C throughout the anaesthesia and operation and throughout the ischaemia and first 1-2 h of reperfusion using a ho meothermic heating blanket. EEG was recorded from platinum electrodes in the scalp.
Induction of ischaemia
Ischaemia was induced by hypovolaemia and carotid ligation. Arterial blood was withdrawn to lower the MABP to 80 mm Hg. The carotid arteries were then oc cluded, and additional blood was withdrawn until the MABP was 50 mm Hg and the EEG was isoelectric. The ischaemic period was measured from the onset of EEG isoelectricity. MABP was maintained at 50 mm Hg by continual withdrawal and reinfusion of blood. At the end of the ischaemic period, the carotid snares were released and the shed blood was reinfused to restore MABP to > 100 mm Hg. The neck wound was infused with 1%
J Cereb Blood Flow Metab. Vol. 10, No.3, 1990 lignocaine and sutured. Suxamethonium chloride was dis continued. Independent respiration was established within 30--60 min, and the animals were extubated and introduced to an oxygen-enriched atmosphere. During these initial stages of recovery, diazepam (0.4 mg/kg i.v.) was administered. When locomotor activity returned (9{}-120 min), animals were disconnected from the blood pres sure transducer and placed in a cage. In the group in which drug administration occurred at 5 and 10 h post ischaemia, body temperature was measured hourly for the first 8 h after ischaemia and once on day 2.
Postoperative care
Nutritional support was provided on day 2 by three injections of Duphalyte (0.5 ml i.p.; Duphar Veterinary Ltd.). Animals not eating pellets were fed with Complan (Crookes Health Care) until they were able to feed them selves.
Drug treatments
D-( -)-2APH at 100 and 330 mg/kg (Monsanto, St.
Louis, MO, U.S.A.), CPP at 3.3 and 10 mg/kg (Dr. J. C. Watkins, Bristol University), CGS 19755 at 3.3, 10, and 30 mg/kg (Dr. J. Lehmann, Ciba Geigy Ltd.), MK801 at 0.3, 1, and 3 mg/kg (Dr. G. Woodruff, Merck, Sharp & Dohme Ltd.), and dextrorphan at 2, 6, 18, and 54 mg/kg (Roche Products Ltd.) were dissolved in saline and in jected intraperitoneally using two different dosing sched ules ("early" and "delayed") (Table O. Ischaemia con trols were performed concurrently with drug-treated an imals.
Histology
At the end of the 7-day postischaemic period, animals were anaesthetised with pentobarbitone (45 mg/kg i.p.) and perfused via the ascending aorta with 250 ml of All drug-infused animals were SUbjected to the same 10-min ischaemic insult as the ischaemia (no drug) controls. PI, post ischaemia. For abbreviations see the text.
40% formaldehyde solution/glacial acetic acid/methanol (1: 1 :8) preceded by a brief saline wash at a pressure of 120 mm Hg. The brain was removed immediately and was stored overnight in the above-described solution prior to paraffin embedding. Sections (10 !-lm) were stained with cresyl fast violet for light microscope examination. Pathology was assessed at two hippocampal levels (4.0 and 3. 2 mm anterior to the interaural line) (Konig and Klippel, 1963) .
CAl cell counts were performed using an ocular grid piece (magnification x640), along a predetermined dis tance of three grid lengths (3 x 470 !-lm) between the CA/CA2 border and the subiculum. For each animal a mean number of CAl cell counts was calculated from eight separate assessments; at each of the two hippocam pal levels, counts were performed on both the left-and the right-hand sides of the brain on two nonconsecutive sections. All values are given as means ± SEM. Evalua tion of significant differences between cell counts in con trol and treatment groups was performed using one-way analysis of variance (ANOV A) followed by a contrast analysis comparing treatment groups or by Dunnett's test for comparison of individual groups with the ischaemic control group. Table 2 demonstrates that during the post ischaemic period, P aco2 and MABP were within normal limits in all experimental groups. P a02 some times exceeded 220 mm Hg in the free-breathing animals owing to the administration of an oxygen enriched atmosphere. Lactic acidosis was often prominent 20 min after ischaemia and persisted into the second hour postischaemia. Throughout the postischaemic period, generalised seizures were ab sent in all animals.
RESULTS
Physiological variables
Temperature
Following disconnection from the homeothermic heating blanket system, body temperature did not alter significantly. In all delayed drug administra tion groups, mean body temperature was 36. 9 ± O.SOC during the 24-h postischaemic period. At 6 h postischaemia (1 h after the first drug injection), mean body temperature was 36. 7 ± 0.2DC (i. e. , drug administration had no apparent effect on body tem perature). At 24 h body temperature was again nor mal (37. 0 ± 0.2DC).
Mortality
In the ischaemic "control" group, 1 of 19 animals died (at 3 h postischaemia and reperfusion, the an imal failed to resume independent respiration). In the group subjected to ischaemia with early drug administration, five of six animals died following injection of MK801 3 mg/kg i.p. (two animals died at 3 h postischaemia without regaining the ability to breathe independently, two animals died at 24-30 h postischaemia, and the fifth died at 72-78 h post ischaemia).
Hippocampal pathology
In all ischaemic groups (no drug and drug treated), cytopathology was mostly restricted to the CAl region of the hippocampus. Elsewhere in the hippocampus only the occasional "dark" cell and peri neuronal oedema around the CA3, CA4, and dentate granule cells were evident.
Ventilated controls (n = 6)
In the CAl region of ventilated control animals, pyramidal cell bodies and nuclei appeared rounded and contained a visible nucleolus. The mean num ber of CAl neurones counted along three grid lengths was 406 ± 13 ( Fig. 1 ).
Ischaemia controls (n = 18)
CAl pyramidal cell loss and gliosis were exten sive following 10 min of ischaemia and 7 days of reperfusion. Some remaining cells appeared nor mal, with a visible nucleolus. Dark shrunken trian gular cells, "ischaemic cell change" (Spielmeyer, 1932) , were infrequently seen scattered among the normal CAl neurones. These ischaemic cells were also occasionally observed in the CA4 region and to a lesser extent in the CA3 and dentate granules cells.
The mean number of CAl neurones counted within the three grid lengths was 157 ± 22, which represents a 61 % loss of neurones. The variability of outcome in this model of ischaemia is shown in Fig. 1 .
Administration of NMDA antagonists
Early administration (+ IS min, +5 h postischaemia): competitive antagonists 0-( -)-2APH, CPP, and CGS 19755 treatments all provided a significant (ANOVA) protective effect against delayed neuronal death in the CAl region of the hippocampus. For 0-( -)-2APH neither of the two treatment groups was significantly different from ischaemic control by Dunnett's test, but 0-( -)-2APH treatment was different from control by contrast analysis (p < 0.01). After CGS 19755 at 10 mg/kg, there was only a 16% loss of CAl cells (p < 0.01 compared with ischaemic control, Dunnett's test), and after CPP there was a 23% loss (p < 0.05, Dunnett's test). Within the band of CAl cells, there were darker, slightly irregularly shaped cells, which were more evident than in the ischaemic animals (in Readings taken following 10 min of ischaemia: 1, + 20 min, animal ventilated on 70% N20/30% 02; 2, + 40-90 min, animal freely breathing 02-enriched air; 3, +4 h postischaemia; 4, +6 h postischaemia (1 h post first injection); 5, +24 h postischaemia.
which these "ischaemic" cells have presumably
Early administration: noncompetitive antagonists disappeared to be replaced with glia). Such darker, MK801 at l. 0 mg/kg and dextrorphan at 54 mg/kg irregularly shaped cells are not included in the CAl provided a significant (p < 0.05 and p < 0.01, recell count, although they may be viable. spectively) protective effect against selective cell 
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loss. The type and degree of damage were similar to those exhibited by animals treated with competitive antagonists, with a 30% (MK801 1 mg/kg) or a 23% (dextrorphan 54 mg/kg) loss of CAl neurones.
Delay ed administration (+ 5 and + 10 h postischaemia)
Delaying the injection times to 5 and 10 h post ischaemia abolished the protective efficacy of both CGS 19755 and MK801 even when the dose of both drugs was increased to three times the effective dose with early administration (Fig. 2) have considered competitive and noncompetitive antagonists independently and have employed a va riety of experimental models (Simon et aI., 1984a; Boast et aI., 1987 Boast et aI., , 1988 Foster et aI., 1987; Gill et aI., 1987 Gill et aI., , 1988 McDonald et aI., 1987; Prince and Feeser, 1988; Steinberg et aI., 1988; Swan et aI., 1988; Michenfelder et aI., 1989; Pulsinelli, 1989 (Davies et aI., 1986) . Similarly, protection by the noncom petitive antagonists' correlates with their in vitro displacement of eH] 1-(2-thienyl)cyclohexyl piperi dine (Wong et aI., 1988) . For the two classes of antagonist, there is a correlation between cerebro protection and (a) in vivo anticonvulsant activity and (b) in vitro NMDA antagonism. This compari son is analysed here in more detail.
Competitive NMDA antagonists In our previous study employing the same rat model of forebrain ischaemia (Swan et aI., 1988) , 0-( -)-2APH at 675 mg/kg given prior to ischaemia and at 4 and 10 h postischaemia was shown to pro-tect the CAl field of the hippocampus. Our new data suggest that lower doses may also be protective but do not allow precise definition of the threshold dose. In the gerbil 2APH at 100 mg/kg given four times was protective (in the absence of temperature control) (Boast et aI., 1987 ) (see Table 3 ). Cerebro protection in the gerbil apparently requires a higher dose of CPP (30 mg/kg) but the same dose of CGS 19755 (10 mg/kg) compared with our rat study (Boast et aI., 1988) (CGS 19755) nM (Lehmann et aI., 1988a) . The ratio of these values is very close to the ratios obtained by taking a mean of the cerebroprotective doses for gerbils and rats (see Table 3 ).
Noncompetitive antagonists
The minimal cerebroprotective doses we report here are similar to effective doses reported in other species with similar or different models. Thus, MK801 at 1 mg/kg was the lowest dose providing significant protection when administered post ischaemia to gerbils undergoing 5 min of forebrain ischaemia (Gill et aI., 1988) . In rabbits undergoing a 1-h occlusion of the left internal carotid and anterior Cerebroprotection: minimum dose (fLmoIlkg) providing signif icant protection against hippocampal damage following 5 or 20 min of ischaemia in gerbil or delayed cell loss in hippocampal CAl region following 10 min of ischaemia (this study) in rat. Anticonvulsant ED5 0 (fLmoIlkg i.p.) for suppression of clonic phase of sound-induced seizures in DBA/2 mice. For abbrevia tions see the text.
a Boast et al. (1988 ). b Groucher et al. (1982 .
C Boast et al. (1987) . d Chapman et al. (1987) .
e Lehmann et al. (l988a) . I Gill et al. (1988) . g Chapman and Meldrum (1989) . 
Duration of action
The competitive and noncompetitive NMDA an tagonists differ in their durations of action, prima rily because of differences in both their plasma and their brain clearance times. A functional test of this is provided by studying the time course of anticon vulsant action in DBAl2 mice (Chapman and Mel drum, 1989) . This is shorter for CPP (2 h) than for 2APH and CGS 19755 (4 h).
Molecular mechanism
Noncompetitive antagonists demonstrate an ago distinction to be made between the two types of NMDA antagonist. Dextrorphan may be a candidate for clinical trial in stroke. We have demonstrated that systemic ad ministration of this drug can significantly reduce se lective ischaemic neuronal loss. Dextrorphan (10-35 mg/kg i.p.) has also been shown to decrease in farction in neonatal rats subjected to hypoxia ischaemia (Prince and Feeser, 1988) . Dextrorphan is the active metabolite of dextromethorphan, which is a clinically available (or, indeed, over the-counter) oral antitussive agent that seems to be devoid of potential addictive narcotic-opiate effects (Isbell and Fraser, 1953) . Recently both compounds have come under close scrutiny because they have been shown to be potent NMDA antagonists (Church et aI. , 1985) , capable of reducing glutamate and NMDA neurotoxicity (Choi, 1987; Choi et aI. , 1987) and attenuating hypoxic injury in neuronal culture (Goldberg et aI. , 1987) . This effect is appar ently not mediated at the classic opiate receptors where the levorotatory enantiomer of dextromethor phan, levorphanol, is more potent, because levor phanol is less effective as a neuroprotective agent. This potency ratio of neuroprotection is consistent with an NMDA receptor-mediated effect via the PCP-IT-receptor (Lodge and Anis, 1982; Choi et aI. , 1987) .
Mechanism of cerebroprotective action
NMDA antagonists reduce excitation either lo cally in the CAl pyramidal cell region or at more distant sites. The anticonvulsant action of NMDA antagonists does not necessarily occur directly at the site of initiation of the seizure discharge. Limbic seizure activity can be attenuated following very low concentrations of 2APH focally injected into the entopeduncular nucleus, lateral habenula, me diodorsal nucleus of the thalamus, and prepiriform cortex (Millan et aI. , 1986; Patel et aI., 1986 Patel et aI., , 1988 . Systemically administered NMDA antagonists may therefore exert their cerebroprotective effect at any of these areas, which are all interconnected with the hippocampus (Millan et aI., 1986; Patel et aI. , 1988) .
Another distant action of NMDA antagonists is via the ascending monoaminergic and cholinergic systems, which can be activated by glutamatergic inputs. Striatal ischaemic damage is enhanced by activation of the nigrostriatal dopaminergic system (Globus et aI., 1987) , whereas hippocampal isch aemic damage is attenuated by activation of the lo cus coeruleus noradrenergic system (Blomqvist et aI., 1985) .
Cerebroprotection could also be achieved via modification of systemic factors. It has been suggested that the neuroprotection seen with MK801 is due to a reduction in core or cerebral temperature (Pulsinelli, 1989) . We have measured temperature in the delayed administration group and shown that there is no direct correlation between body temper ature and protective efficacy of CGS 19755 and MK801.
Endocrine factors could also contribute to cere broprotection. Stress-induced release of glucocorti coids may increase ischaemic pathology (Sapolsky and Pulsinelli, 1985) . [The anxiolytic component of NMDA antagonist action might reduce this effect (Clineschmidt et aI., 1982) .]
Therapeutic window
We have shown that systemic administration of competitive or noncompetitive NMDA antagonists starting early in the reperfusion phase (+ 15 min) can provide a protective effect against selective CAl neuronal loss. Delayed administration (starting at + 5 h) of either competitive or noncompetitive antagonists does not provide a significant protec tion.
In a previous study in the gerbil, the protective effects of CGS 19755 (30 mg/kg) have been found to be apparent at long delays (1, 2, and 4 h) after isch aemia (Boast et aI. , 1988) . However, the maximal effect is attained when the interval between reversal of ischemia and drug administration is at a mini mum. The neuroprotective effectiveness of MK801 has also been shown to follow a dose-and time dependent profile in the gerbil, with MK801 at 0.3 mg/kg being effective only when administered dur ing carotid occlusion, MK801 at 1 mg/kg adminis tered 30 min after ischaemia producing a more dra matic protective effect than when administered af ter 2 h, and MK801 at 3 and 10 mg/kg being effective at delays of up to 24 h (Gill et aI., 1988) .
These studies illustrate that omitting the early postischaemic injection of antagonist abolishes cerebroprotection. Even when CGS 19755 and MK801 were injected at high doses of 30 and 3 mg/ kg, respectively, at the delayed times, significant protection was not achieved. There thus appears to be an important difference between gerbils and rats in terms of protection following delayed administra tion of NMDA antagonists. There is probably no difference between competitive and noncompetitive antagonists in terms of effectiveness with delayed postischaemic administration. Events involving the NMDA receptor very early in the reperfusion phase (such as increased burst firing and enhanced cal cium entry into vulnerable neurones) thus seem vi tal to the secondary development of the excitotoxic lesion.
The principal clinical counterpart of the current study is brain damage following cardiac arrest. Emergency treatment is usually available to such patients when the arrest occurs in a hospital setting. Thus, there is a real prospect of being able to initi ate therapy within 15 min of the ischaemia. Our data support the case for clinical trials of NMDA antag onists in transient cerebral ischaemia (Schwarcz and Meldrum, 1985; Albers et aI., 1989) .
